May 10, 2004 Vol. 82, Iss. 19

Back Issues
2007 2006 2005 2004 2003 2002 2001 2000 1999 1998
Latest News RSS Feed What is this?
Join ACS

	Table of Contents May 10, 2004 Volume 82, Number 19 p. 3
	PROTEIN DRUGS Rapid transformation in business and research has turned large drug firms into biotech players, while contract service firms move into life-cycle management.
	COVER: Photodisc

	BIODEFENSE STRATEGY New biodefense labs are going up, along with concerns about safety and costs. SAUDI SHOOTING Terrorist incident at Yanbu petrochemical facility may affect other joint ventures in the region. PLASTIC OCEANS Environmental study finds microscopic bits of plastics are accumulating in oceans. COPPER BOUND NO and O2 bind to copper in metalloenzymes in ways never before seen in nature. NUCLEAR POWER Consortia seek federal help in obtaining permits for a new generation of plants. RESPONSIBLE CARE New ACC website will give company data on health, safety, and environmental practices. DRUG DISAPPROVAL Committee recommendation on two cancer drugs has ramifications for fine chemicals producers. GREEN CHEMISTRY ACS selects White House's Paul Anastas to be director of the Green Chemistry Institute. SCIENCE INDICATORS Biennial report is a catalyst for mulling over R&D trends.

	BUSINESS CONCENTRATES CEDARBURG PHARMACEUTICALS Founders reluctantly turned to venture capital, but now revel in firm's robust growth. JOSEPH A. MILLER JR. C&EN talks with Corning's chief technology officer, who opted for new challenges after retiring from DuPont.

	GOVERNMENT CONCENTRATES REACH PROPOSAL Key players from U.S. and Europe share views on imminent EU legislation. CHEMICAL ARMS DESTRUCTION Obstacles to complying with Chemical Weapons Convention raise proliferation issues. HINDSIGHTS A debate centers on whether the U.S. should build more nuclear weapons.

	SCIENCE/TECHNOLOGY CONCENTRATES MAIN-GROUP REVIVAL ACS symposium highlights new developments in the resurgent field of main-group chemistry. FIRST-TIME DISCLOSURES Researchers from major pharmaceutical companies introduce new drugs at ACS symposium. FLEXIBLE RECEPTORS Docking programs can overlook important potential drug candidates because of flexibility of the protein itself. NEW PRODUCTS

	RARE BOOKS Chemical Heritage Foundation has purchased a collection spanning six centuries of science.

	LETTERS AWARDS PEOPLE NEWSCRIPTS